Oncolytics Biotech Inc. (ONCY)

[masslanding]

Rbc has new target $1.50 with $3.00 upside
Today, very early RBC has issued a new report for ONC trading price.
sighting the most recent N.R.and expectations of phase 3 with breast cancer trial.
They have a noted very conservative target of $1.50, with an upside of $3.00/share.
in addition to pages of data etc,nthey sight upside catalyst as essentially anything beyond where we are now.
They say for example, starting PH3 would be catalyst enough to move target upwards.
My comments; for the first time in many years onc woukd appear to be moving solidly in the right direction.
( I refer to the clinical/business, not the share price).
The share price, while doing well last few weeks has a long way to go to be in- line with where it can & should be.